反応式
[CH:1]12[CH2:7][CH:4]([CH2:5][CH2:6]1)[CH2:3][C@@H:2]2[NH:8][C:9]1[S:10][C:11]([CH2:16][CH:17]2[CH2:22][CH2:21][N:20]([C:23]([C:25]3[CH:26]=[C:27]([CH:39]=[CH:40][CH:41]=3)[O:28][CH2:29][CH2:30][NH:31][C:32](=[O:38])OC(C)(C)C)=[O:24])[CH2:19][CH2:18]2)([CH3:15])[C:12](=[O:14])[N:13]=1.NCCOC1C=[C:48]([CH:73]=[CH:74]C=1)[C:49](N1CCC(CC2(C)SC(N[C@H]3CC4CC3CC4)=NC2=O)CC1)=[O:50].O1C=CC(C(O)=O)=C1.CCN=C=NCCCN(C)C.C1C=CC2N(O)N=NC=2C=1.C(N(CC)CC)C>>[CH:1]12[CH2:7][CH:4]([CH2:5][CH2:6]1)[CH2:3][C@@H:2]2[NH:8][C:9]1[S:10][C:11]([CH2:16][CH:17]2[CH2:18][CH2:19][N:20]([C:23]([C:25]3[CH:26]=[C:27]([CH:39]=[CH:40][CH:41]=3)[O:28][CH2:29][CH2:30][NH:31][C:32]([C:73]3[CH:48]=[CH:49][O:50][CH:74]=3)=[O:38])=[O:24])[CH2:21][CH2:22]2)([CH3:15])[C:12](=[O:14])[N:13]=1参加物
7
実験手順
The title compound was prepared according to the procedure described in the preparation of tert-butyl 2-(3-(4-((2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-4-oxo-4,5-dihydrothiazol-5-yl)methyl)piperidine-1-carbonyl)phenoxy)ethylcarbamate by using 5-((1-(3-(2-aminoethoxy)benzoyl)piperidin-4-yl)methyl)-2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methylthiazol-4(5H)-one (93 mg, 0.19 mmol), 3-furoic acid (Aldrich, 39 mg, 0.35 mmol), EDCI (Aldrich, 74 mg, 0.38 mmol), HOBt (Aldrich, 5.2 mg, 0.038 mmol) and triethylamine (Aldrich, 39 mg, 0.38 mmol, 2.0 eq). The title compound was obtained as an off-white solid (89 mg). MS (ESI, pos. ion) m/z. 579 (M+H).
後処理
- customThe title compound was prepared
出典と根拠
- ORDレコード
- ord-7f250aae5c6e460f92c0e6dd52144c49
- 出典データセット
- uspto-grants-2013_09
- 特許番号
- US08541592B2
関連ノート
読み込み中…